On September 11, HBM HOLDINGS-B fell 5.21% in regular trading, trading at HKD 13.44 per share, with turnover of approximately HKD 46.66 million.

The decline came amid broad weakness across the biotechnology sector. Within the sector, INNOVENT BIO fell 2.17%, AKESO fell 2.03%, DUALITYBIO-B fell 2.11%, BEONE MEDICINES fell 1.64%, and 3SBIO fell 1.16%, reflecting widespread selling pressure on biotech names.

On the fundamental side, the company's recently disclosed interim results showed H1 revenue of USD 122 million, up 20.9% year-over-year, driven primarily by molecular licensing and collaboration income of USD 113 million. However, net profit fell 11.16% to USD 64.85 million, while operating cash flow swung from a net inflow of USD 61.66 million to a net outflow of USD 14.34 million, raising concerns over earnings quality. Management expenses also rose materially due to increased personnel costs and IP-related expenditures.

Additionally, southbound capital has net sold approximately one million shares over the past 20 trading days, signaling a cautious stance from mainland investors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)